

Association of oral candidal species with human immunodeficiency virus patients of West Godavari district, Andhra Pradesh – An *in vitro* study

R. Mounika¹, Govindraj K. Nalabolu², N. Pallavi³, Smita S. Birajdar⁴

¹ Department of Oral Pathology, Vishnu Dental College, Rajarajeswari Multispeciality Dental Clinic, ⁴Department of Oral Pathology and Microbiology, Vishnu Dental College, Bhimavaram, ²Department of Oral Pathology and Microbiology, GSL Dental College, Rajahmundry, ³Department of Oral Pathology and Microbiology, Anil Neerukonda Institute of Dental Sciences, Vishakapatnam, Andhra Pradesh, India

Abstract

Introduction: Human immunodeficiency virus (HIV) infection is a major worldwide health problem characterized by progressive immunosuppression. The morbidity of HIV patients is due to its association with opportunistic infections among which oral candidiasis is common. Regardless of HIV status, candidiasis can prevail when their immune system is depressed. Oral candidiasis can thus serve as a useful marker for both restoration of immune functions and HIV disease progression. Routine identification of *Candida* species is laborious and time-consuming. HICHRUM agar stains different species into different colors facilitating rapid reliable identification of candida species as they differ in their virulence and sensitivity to antifungal drugs.

Materials and Methods: This cross-sectional study includes a total of 200 HIV seropositive patients from Anti-Retroviral Therapy Centre, West Godavari District. Unstimulated saliva samples were collected in a screw-capped universal container. Five microliters of each sample using a sterile inoculating loop is streaked on the chromogenic agar culture media. The colonies formed are counted using a magnifying glass and LAPIZ colony counter. Candidal colony-forming units per milliliter were analyzed, compared and correlated among different study groups. Different candida species were also identified in the study.

Results: Nonalbicans *Candida* was the most common species isolated in our study accounting for 53% and *Candida albicans* accounting for 47%. Considering initial and final CD4 counts, there is improvement in patients on retroviral therapy.

Conclusion: Identification of the species is important for epidemiological reasons and for treatment purposes to ensure a better prognosis since some species present reduced susceptibility to azoles.

Keywords: *Candida*, CD4 count, highly active antiretroviral therapy, human immunodeficiency virus-positive patients, nonalbican candida

Address for correspondence: Dr. N. Pallavi, Department of Oral Pathology and Microbiology, Anil Neerukonda Institute of Dental Sciences, Sangivalasa, Visakhapatnam - 531 162, Andhra Pradesh, India.

E-mail: drpallavi456@gmail.com

Submitted: 14-Dec-2020, **Revised:** 18-Jan-2021, **Accepted:** 20-Feb-2021, **Published:** 14-May-2021

Access this article online

Quick Response Code:



Website:

www.jomfp.in

DOI:

10.4103/jomfp.jomfp_504_20

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

How to cite this article: Mounika R, Nalabolu GK, Pallavi N, Birajdar SS. Association of oral candidal species with human immunodeficiency virus patients of West Godavari district, Andhra Pradesh – An *in vitro* study. J Oral Maxillofac Pathol 2021;25:147-53.

INTRODUCTION

Human immunodeficiency virus (HIV) infection is one of the most devastating diseases leading to be a very serious health issue.^[1] It drastically changes the life of the patient in terms of quality leading to Acquired Immunodeficiency syndrome (AIDS). AIDS declared an epidemic is affecting all sectors of people all over the globe.^[2]

UNAIDS commitments by 2020 are 90-90-90 targets: 90% of people living with HIV know their status, 90% of people living with HIV who know their HIV-positive status are accessing treatment and 90% of people on treatment have suppressed viral loads. Globally, 2019, at its end, affirms 1.7 million became newly infected with HIV, 81% (38 million) people knew their HIV status, 67% (25.4 million) were on antiretroviral therapy (ART) and 59% had suppressed viral loads. Access to ART has averted an estimated 12.1 million AIDS-related deaths since 2010. The setbacks of 2020 targets disrupted by the pandemic COVID-19 impacted AIDS mortality levels. UNAIDS is urging countries to fight the colliding epidemics of HIV and COVID-19, as we cannot afford to lose the gains that took so much effort to win.^[3]

HIV infection causes depletion of CD4 cells, low CD4 cells count of $<200/\text{mm}^3$ has considered being an indication of active disease progression, further which determines the immune status of patient. Hence the CD4 cell count is essential in monitoring the disease advancement as well as to plan a suitable therapy.^[4] Such immunosuppressed patients are prone to opportunistic infections particularly pneumocystosis, oral candidiasis and neoplasms.^[5]

Fungal infections play a greater clinical challenge in HIV patients in severe immunosuppressive conditions.^[6] Currently, there are 200 species within the genus candida, in which six species; *C. albicans*, *C. glabrata*, *C. tropicalis*, *C. parapsilosis*, *Candida krusei* and *C. lusitaniae* are the most commonly associated with human infection.^[7] Dentist plays a pivotal role in diagnosing AIDS, as oral lesions especially oral candidiasis manifest early in HIV infection. HIV patients with oral candidiasis have 2.5 times more progressive risk to AIDS than without oral candidiasis.^[4,7,8] Routine identification of candida species is laborious and time-consuming. To overcome this, HICHRON agar is used which stains different species to different colors that facilitates a simple, rapid and reliable method for identification of *Candida* species.^[9]

The literature revealed no studies on HIV patients residing in West Godavari district and their factors associated

with the disease process. The present study thus made an attempt to determine species diversity among candida isolates and their associations in both symptomatic and asymptomatic HIV seropositive patients of West Godavari district population. It also correlates CD4 count with the predominant Candidal species which paves a path for investigators to unveil a better diagnostic checkpoint and facilitate an active ART.

MATERIALS AND METHODS

The cross-sectional study included a total of 200 HIV seropositive patients from ART Centre, West Godavari District. An informed consent was obtained from every subject for inclusion in the study and performing the test. A detailed clinical history was recorded for all cases from archives of the ART center. Unstimulated saliva sample was collected in screw-capped universal container and stored at 4°C. The samples were transported to the microbiology laboratory for further analysis.

Identification of Candida: Samples were centrifuged at 5000 rpm for half an hour. Five microliters of each sample using a sterile inoculating loop was streaked on to the chromogenic agar culture media and incubated at 37°C for 48–72 h. HICHRON agar, a yeast differential and selective medium, allows recognition of mixed yeast cultures collected from clinical specimen. This media differentiates candida population by colonial morphology and color generated by a chromophore in the agar.

Statistical analysis

The statistical analysis was performed using SPSS software, (IBM Inc, Chicago, Illinois, USA) version 16. Pearson's Chi-square test was used for comparing the different candidal species with demographics in study groups. $P < 0.05$ was considered statistically significant.

RESULTS

Out of 200 HIV seropositive patients, 99 were male and 101 were female. Majority of patients belong to the age group between 26 and 45 years with a mean age of 31 years. By occupation, 112 (56%) patients were daily wage laborers, 50 (25%) were housewives, 25 (12.5%) were farmers, 8 (4%) were students and 5 (2.5%) were teachers [Graph 1].

Based on CDC classification CD4 counts were recorded, 90 patients showed initial CD4 count <200 , 76 patients were in the range of 200–500 and 34 patients at 500 count. After the administration of highly active ART (HAART) for a period of 2–3 years, 7 patients showed a final CD4 count below 200, 48 were in the

range of 200–500, whereas 145 patients crossed the CD4 count over 500. Significant observations ($P = 0.00$) from our study revealed a drastic difference between the initial and final CD4 count among students (609), followed by teachers (429), housewives (398), farmers (373) and daily wage laborer (322) [Graph 2].

The association between the age, gender and occupation with *C. albicans*, *C. krusei* and *C. glabrata* was observed in the study. Out of 200 patients, 152 HIV patients in the age range of 26–45 years predominantly showed Non-albicans candida (NACs). However, there was no statistically significant difference in the prevalence of various candida species.


Qualitative assessment of *Candida* species was thus done in our study to differentiate the *Candida albicans* species from NACs using Hicrome agar media. Majorly three species were identified, among which *C. albicans* isolates appeared green in color, candida glabrata isolates in cream and candida krusei isolates in pale pink color [Figure 1]. Nonalbicans candida (106, 53%) was the species predominantly recovered in our study. *C. glabrata* (72, 36%) and *C. krusei* (34, 17%) were the two NACs that were persistently identified [Graph 3].

Quantitative assessment was performed by disclosing the number of candida colonies evolved in our study. *C. albicans* (3473) have shown a greater proportion of colonies followed by *C. glabrata* (2320) and *C. krusei* (961) [Graph 3 and Figure 2].


Colonization by more than one candida species has been reported in the literature. In our study, 104 (52%) of the patients were colonized by atleast 2 species and association was predominantly between *C. albicans* and *C. glabrata* 67 (64%). HIV patients with no clinical candidiasis also disclosed candidal colonization, emphasizing identification of asymptomatic candidal patients.

DISCUSSION


Oral microbiome and the immune system interplay encompass various strategic scuffles in health and disease.^[10] The immune system, a double edge sword, congregate events in host defense on one hand while on other, aberrations ground to immunodeficiency.^[11] Acquired immunodeficiency syndrome (AIDS) is a collection of symptoms or diseases caused by HIV. HIV infects and destroys immune cells resulting in person’s vulnerability to infections. It invades various immune cells (e.g, CD4+ T cells, macrophages and monocytes) resulting in a decline in CD4+ T cell numbers below the critical level leading to AIDS.^[12]



Graph 1: Distribution of demographic profile among study subjects – slight female predominance with prevalence in the age group of 26–35 and the most common social group affected being the daily wage laborers



Graph 2: Immunological profiles of study subjects – influence of highly active antiretroviral therapy treatment on various occupations among which students have shown a drastic change between the initial and final CD4 count



Graph 3: Distribution of *Candida* isolates among study population – NACs are the predominant species isolated in the study. On comparing the number of colony-forming units, *Candida albicans* species are under greater proportion when compared to NACs

Our study revealed the mean age of HIV seropositive patients with both symptomatic and asymptomatic candidiasis as 31 years with a range of 26–45 years. Das *et al.* 2016, Maheswari *et al.* 2016, observed similar findings in their studies. They disclosed 26–40 years as the most commonly affected age, at which they are sexually active. In this study, the authors hypothesized that younger people are more commonly infected with HIV considering the fact that, this age group is at an edge of physical and emotional transformation which navigate




Figure 1: *Candida albicans* isolates show green colored colonies, *candida glabrata* isolates appearing cream color and *candida krusei* isolates in pale pink color

them toward the sexual urge. Authors also presumed that vertical transmission, intergeneration sex, transgender sex, homosexuality, intravenous drug abuse and blood transfusion are the possible risk zones encountered in the younger people.^[13,14] This can be ascribed to their experimental nature and lack of knowledge that indulged them to infection. As seen in Sravya Kurapati 2012; Kothari and Goyal 2001; Kumarasamy *et al.* 1995 and Kaur *et al.* 1992 studies in India, sexual mode of transmission was the most common in 32 (53.3%) patients (heterosexuality accounting for 94% of these), followed by intravenous drug abuse (8.3%) and blood transfusion (5%).^[15-19]

Early diagnosis of HIV infection, access to medical care and HAART plays an important role in HIV-related oral disease prevention. A study conducted by Tappuni and Fleming 2001 in 284 HIV-infected patients in the United Kingdom found that HIV patients on dual or triple HAART were significantly less likely to have HIV-related oral manifestations, reductions in viral load and increase in CD4 counts.^[20,21] This helps in improving the patient's quality of life by reconstituting the immune system.^[22] On analyzing occupation, daily wage laborers were mostly infected with HIV, followed by housewives, farmers, students and teachers. Similar observations were made by Annapurna *et al.* 2012, Kerdpon *et al.* 2004, in their study on Tamil Nadu, South and North Thai patients.^[22,23] Despite their smaller proportion, students had shown remarkable improvement after HAART. The authors hypothesized lifestyle, nutrition, general health and body response to HAART might be the imparting factors for such progression among students.

In the current study, both initial and final CD4 counts were recorded along with the period of HAART administration.




Figure 2: Number of colonies formed were more in *Candida albicans* species when compared to NACs

Observations exposed a significant reduction in clinical as well as oral manifestations along with an improvement in CD4 count. Our study was in accordance with Samaranyakayake, Tsang 1999, Ranganathan *et al.* 2000, Kerdpon D 2004, Nantez *et al.* 2014 who found oral candidiasis as the only lesion which had a significant association with CD4 count. Individuals with oral candidiasis are thrice as likely to be immunosuppressed as those without candidiasis. These circumstances oral examination as a crucial and beneficial signpost in the management of the HIV patients.^[14,23-26]

Goulart *et al.* 2018 and Fidel 2011 in their studies observed oropharyngeal candidiasis as the first clinical sign of HIV.^[27,28] Persistent colonization of oral cavity by candida species has gained high incidence in HIV patients. Considering it, as a chief factor, it can be used as an important marker in the disease initiation and progression. Colonization of candida varies with factors such as smoking, alcohol consumption, gender, geographical, climatic, ethnic differences, immune status, CD4 count, HIV viral load and use of HAART. Although the predominant species among candida was albicans, there was an increased percentage of NAC species which had effect on the health of HIV patients.^[5,29] Hyphae, biofilm formation, acid proteinase and phospholipase production are considered the most important virulence factors facilitating the candida to become pathogenic in HIV seropositive patients. NACs being deficient in total or partial virulence factors the candida species actually possess are less virulent when compared to the albican species.^[30-32]

Out of 200 subjects in the study, *C. albicans* species was observed in 94 (47%) patients, while NACs (106, 53%) was the species predominantly recovered in our study.

Chalacombe *et al.* 1995 and Enwuru *et al.* 2008 reported 54% and 59.5% of NACs, respectively, in their studies.^[33,34] In contrast, studies of Latiff *et al.* 2004, Menezes *et al.* 2015, Clark *et al.* 2017 and Khedri *et al.* 2018 reported 86%, 67.6%, 71.8% and 52.9% of *C. albicans*, respectively.^[5,29,35,36] Among NACs, *C. glabrata* (72, 36%) and *C. krusei* (34, 17%) were the two variants that are persistently identified. Studies carried out by Sao Paulo disclosed *C. glabrata* as the most frequently isolated NACs which is in accordance with the present study.^[37] Conversely, contradictory observations were disclosed in western country studies which revealed *C. tropicalis* and *C. parapsilosis* as the frequently isolated species.^[38] All such elucidations emphasize that distribution of NACs has geographical precision^[39] and also emerging drug-resistant NACs profile in HIV patients confront the challenge to select an empiric treatment.

Although NACs were identified in considerable percentage of our study subjects, a number of *C. albicans* colonies prevailed over them. In spite of intrinsic low susceptibility, NACs have high resistance to azole antifungal agents.^[40] Usage of these drugs in past by HIV patients would have lead for greater proportion of NACs. Protease and transcriptase inhibitor classes of HAART inhibit proteolytic enzymes secreted by Candida species that are crucial for the growth of Candidal hyphae leading to colonization. HIV-positive patients under such HAART eventually resist colonization of Candida and their adherence to the oral mucosa, result of which the number of colonies among NACs was insignificant.^[5]

Colonization by more than one candida species has been reported in the literature. In our study, 104 (52%) of the patients were colonized by atleast 2 species and association was predominantly between *C. albicans* and *C. glabrata* 67 (64%). A study conducted by lakshmansamaranayake *et al.* 1987 exposed the most common yeast combinations isolated from oral samples as *C. albicans* with *C. krusei*, *C. tropicalis* or *C. glabrata*.^[41] In accordance with the present study, Erkose *et al.* 2007, Junqueira *et al.* 2012 and Li *et al.* 2013 have shown predominant association between *C. albicans* and glabrata.^[37,42,43] In disparity, the study of Menezes *et al.* 2015 has shown a predominant association between *C. albicans* and parapsilosis.^[5] Authors predicted the associations could be due to the presence of a specialized set of proteins called adhesins in candida, which mediate the connotation to more than one Candida species and to host cells.^[44]

From the observations of the present study, an increase in CD4 count among HIV patients had shown a strong association with a rise in Candidal colonization. This

encloses a fact that enhancement in CD4 count is required but not sufficient to protect HIV-infected patients from colonization by Candida.^[45] A similar assessment was observed by Erkose *et al.* 2007 and Sanchez-Vargas *et al.* 2005, while De Brito Costa *et al.* 2003 study contradicted our findings.^[42,46,47] Host characteristics such as salivary flow rate, salivary anticandidal proteins and oral hygiene and/or strain features such as virulence are the factors that has to be ruled out for a better confirmation of candida colonization and its association with CD4 count.

Although there were no oral manifestations, substantial candidal growth was observed in our study population which heralded the importance of identifying asymptomatic patients. All asymptomatic patients demonstrated colonization of candidal species which included both albicans and NAC species. The use of antibiotics, a predisposing factor, used in the initial stages of disease would have favored the growth of candida species.^[38] Conversely, regional differences and selective pressure of antifungal drugs might have also changed the trend of infection.^[5] Thus, dentists and clinical microbiologists are at an urge to identify Candida at the species level, to en route appropriate therapeutics and optimize treatment.^[39,48]

CONCLUSION

The colonization of Candidal species is an index to predict immunosuppression in HIV seropositive patients. Identifying candida at its species level will promote in bringing an early first step in the management of HIV patients. However, to incorporate it as an index certain host characteristics, regional parameters, antifungal resistance and the use of HAART should be considered. This outcome can be brought about through a detailed case history given by the patients, lack of which seizes the advancement. Stigma, discrimination and widespread inequalities are the barriers for such a breakthrough. Further investigation notably larger longitudinal studies are warranted to clarify the role of CD4 count, viral load, regional parameters and the influence of ART on manifestations of oral candidiasis.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Šembera M, Radochová V, Slezák R. Dental and oral lesions in HIV-positive individuals in East Bohemia—Czech Republic, Single

- Centre experience. *Acta Medica (Hradec Kralove)* 2015;58:123-7.
2. Warriar SA, Sathasisvasubramanian S. Human immunodeficiency virus induced oral candidiasis. *J Pharm Bioallied Sci* 2015;7:S812-4.
 3. Global AIDS Update 2020: Seizing the Moment. UNAIDS Report. Available from: https://www.unaids.org/sites/default/files/media_asset/2020_global-aids-report_en.pdf. [Last accessed on 2020 Oct 28].
 4. Sen S, Mandal S, Bhattacharya S, Halder S, Bhaumik P. Oral manifestations in human immunodeficiency virus infected patients. *Indian J Dermatol* 2010;55:116-8.
 5. Menezes Rde P, Borges AS, Araujo LB, Pedroso Rdos S, Röder DV. Related factors for colonization by *Candida* species in the oral cavity of HIV-infected individuals. *Rev Inst Med Trop Sao Paulo* 2015;57:413-9.
 6. Nissapatorn V, Sawangjaroen N. Parasitic infections in HIV infected individuals: Diagnostic & therapeutic challenges. *Indian J Med Res* 2011;134:878-97.
 7. Turner SA, Butler G. The *Candida* pathogenic species complex. *Cold Spring Harb Perspect Med* 2014;4:a019778.
 8. Bajpai S, Pazare AR. Oral manifestations of HIV. *Contemp Clin Dent* 2010;1:1-5.
 9. Baradkar VP, Mathur M, Kumar S. Hichrom *Candida* agar for identification of *Candida* species. *Indian J Pathol Microbiol* 2010;53:93-5.
 10. Gao L, Xu T, Huang G, Jiang S, Gu Y, Chen F. Oral microbiomes: More and more importance in oral cavity and whole body. *Protein Cell* 2018;9:488-500.
 11. Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. *Cell Res* 2020;30:492-506.
 12. Abul K, Abbas MD. Diseases of immunity. In: Kumar V, Abbas AK, Fausto N, Robbins SL, Cotran RS, editors. *Robbins and Cotran: Pathologic Basis of Disease*. 7th ed. Philadelphia: Elsevier Saunders; 2005. p. 193-269.
 13. Das PP, Saikia L, Nath R, Phukan SK. Species distribution & antifungal susceptibility pattern of oropharyngeal *Candida* isolates from human immunodeficiency virus infected individuals. *Indian J Med Res* 2016;143:495-501.
 14. Maheshwari M, Kaur R, Chadha S. *Candida* species prevalence profile in HIV seropositive patients from a major tertiary care hospital in New Delhi, India. *J Pathog* 2016;2016:6204804.
 15. Kurapati S, Vajpayee M, Raina M, Vishnubhatla S. Adolescents living with HIV: An Indian profile. *AIDS Res Treat* 2012;2012:576149.
 16. Kothari K, Goyal S. Clinical profile of AIDS. *J Assoc Physicians India* 2001;49:435-8.
 17. Kumarasamy N, Solomon S, Jayaker Paul SA, Venilla R, Amalraj RE. Spectrum of opportunistic infections among AIDS patients in Tamil Nadu, India. *Int J STD AIDS* 1995;6:447-9.
 18. Kaur A, Babu PG, Jacob M, Narasimhan C, Ganesh A, Saraswathi NK, et al. Clinical and laboratory profile of AIDS in India. *J Acquir Immune Defic Syndr* (1988) 1992;5:883-9.
 19. Wadhwa A, Kaur R, Agarwal SK, Jain S, Bhalla P. AIDS-related opportunistic mycoses seen in a tertiary care hospital in North India. *J Med Microbiol* 2007;56:1101-6.
 20. Tappuni AR, Fleming GJ. The effect of antiretroviral therapy on the prevalence of oral manifestations in HIV-infected patients: A UK study. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2001;92:623-8.
 21. Patton LL. Current strategies for prevention of oral manifestations of human immunodeficiency virus. *Oral Surg Oral Med Oral Pathol Oral Radiol* 2016;121:29-38.
 22. Annapurna CS, Prince CN, Sivaraj S, Ali IM. Oral manifestations of HIV patients in South Indian population. *J Pharm Bioallied Sci* 2012;4:S364-8.
 23. Kerdpon D, Pongsirivet S, Pangsomboon K, Iamaroon A, Kampoo K, Sretrirutchai S, et al. Oral manifestations of HIV infection in relation to clinical and CD4 immunological status in northern and southern Thai patients. *Oral Dis* 2004;10:138-44.
 24. Tsang PC, Samaranyake LP. Oral manifestations of HIV infection in a group of predominantly ethnic Chinese. *J Oral Pathol Med* 1999;28:122-7.
 25. Ranganathan K, Reddy BV, Kumarasamy N, Solomon S, Viswanathan R, Johnson NW. Oral lesions and conditions associated with human immunodeficiency virus infection in 300 south Indian patients. *Oral Dis* 2000;6:152-7.
 26. Nanteza M, Tusiime JB, Kalyango J, Kasangaki A. Association between oral candidiasis and low CD4+ count among HIV positive patients in Hoima Regional Referral Hospital. *BMC Oral Health* 2014;14:143.
 27. Goulart LS, Souza WW, Vieira CA, Lima JS, Olinda RA, Araújo C. Oral colonization by *Candida* species in HIV-positive patients: Association and antifungal susceptibility study. *Einstein (Sao Paulo)* 2018;16:eAO4224.
 28. Fidel PL Jr. Candida-host interactions in HIV disease: Implications for oropharyngeal candidiasis. *Adv Dent Res* 2011;23:45-9.
 29. Clark-Ordóñez I, Callejas-Negrete OA, Aréchiga-Carvajal ET, Mouriño-Pérez RR. *Candida* species diversity and antifungal susceptibility patterns in oral samples of HIV/AIDS patients in Baja California, Mexico. *Med Mycol* 2017;55:285-94.
 30. **Wibawa T, Praseno, Aman AT. Virulence of *Candida albicans*: isolated from HIV infected and non infected individuals. Springerplus 2015;4:408.**
 31. Mohandas V, Ballal M. Distribution of *Candida* species in different clinical samples and their virulence: Biofilm formation, proteinase and phospholipase production: A study on hospitalized patients in southern India. *J Glob Infect Dis* 2011;3:4-8.
 32. Vila T, Sultan AS, Montelongo-Jauregui D, Jabra-Rizk MA. Oral Candidiasis: A disease of opportunity. *J Fungi (Basel)* 2020;6:15.
 33. Sweet SP, Cookson S, Challacombe SJ. *Candida albicans* isolates from HIV-infected and AIDS patients exhibit enhanced adherence to epithelial cells. *J Med Microbiol* 1995;43:452-7.
 34. Enwuru CA, Ogunledun A, Idika N, Enwuru NV, Ogbonna F, Aniedobe M, et al. Fluconazole resistant opportunistic oro-pharyngeal *Candida* and non-*Candida* yeast-like isolates from HIV infected patients attending ARV clinics in Lagos, Nigeria. *Afr Health Sci* 2008;8:142-8.
 35. Lattif AA, Banerjee U, Prasad R, Biswas A, Wig N, Sharma N, et al. Susceptibility pattern and molecular type of species-specific *Candida* in oropharyngeal lesions of Indian human immunodeficiency virus-positive patients. *J Clin Microbiol* 2004;42:1260-2.
 36. Khedri S, Santos AL, Roudbary M, Hadighi R, Falahati M, Farahyar S, et al. Iranian HIV/AIDS patients with oropharyngeal candidiasis: Identification, prevalence and antifungal susceptibility of *Candida* species. *Lett Appl Microbiol* 2018;67:392-9.
 37. Junqueira JC, Vilela SF, Rossoni RD, Barbosa JO, Costa AC, Rasteiro VM, et al. Oral colonization by yeasts in HIV-positive patients in Brazil. *Rev Inst Med Trop Sao Paulo* 2012;54:17-24.
 38. Back-Brito GN, Mota AJ, Vasconcellos TC, Querido SM, Jorge AO, Reis AS, et al. Frequency of *Candida* spp. in the oral cavity of Brazilian HIV-positive patients and correlation with CD4 cell counts and viral load. *Mycopathologia* 2009;167:81-7.
 39. Spalanzani RN, Mattos K, Marques LI, Barros PF, Pereira PI, Paniago AM, et al. Clinical and laboratorial features of oral candidiasis in HIV-positive patients. *Rev Soc Bras Med Trop* 2018;51:352-6.
 40. Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS, Rogers PD. Azole antifungal resistance in *Candida albicans* and emerging non-albicans *Candida* species. *Front Microbiol* 2016;7:2173.
 41. Samaranyake LP, MacFarlane TW, Williamson MI. Comparison of Sabouraud dextrose and Pagano-Levin agar media for detection and isolation of yeasts from oral samples. *J Clin Microbiol* 1987;25:162-4.
 42. Erköse G, Erturan Z. Oral *Candida* colonization of human immunodeficiency virus infected subjects in Turkey and its relation with viral load and CD4+T-lymphocyte count. *Mycoses* 2007;50:485-90.
 43. Li YY, Chen WY, Li X, Li HB, Li HQ, Wang L, et al. Asymptomatic oral yeast carriage and antifungal susceptibility profile of HIV-infected patients in Kunming, Yunnan Province of China. *BMC Infect Dis* 2013;13:46.
 44. Mayer FL, Wilson D, Hube B. *Candida albicans* pathogenicity mechanisms. *Virulence* 2013;4:119-28.
 45. Yang YL, Lo HJ, Hung CC, Li Y. Effect of prolonged HAART on oral colonization with *Candida* and candidiasis. *BMC Infect Dis* 2006;6:8.
 46. Sánchez-Vargas LO, Ortiz-López NG, Villar M, Moragues MD,

- Aguirre JM, Cashat-Cruz M, et al. Oral *Candida* isolates colonizing or infecting human immunodeficiency virus-infected and healthy persons in Mexico. *J Clin Microbiol* 2005;43:4159-62.
47. de Brito Costa EM, dos Santos AL, Cardoso AS, Portela MB, Abreu CM, Alviano CS, et al. Heterogeneity of metallo and serine extracellular proteinases in oral clinical isolates of *Candida albicans* in HIV-positive and healthy children from Rio de Janeiro, Brazil. *FEMS Immunol Med Microbiol* 2003;38:173-80.
48. Ravi JR, Rao TR. Estimation of prevalence of periodontal disease and oral lesions and their relation to CD4 counts in HIV seropositive patients on antiretroviral therapy regimen reporting at District General Hospital, Raichur. *J Indian Soc Periodontol* 2015;19:435-9.